SpyGlass Pharma Advances Glaucoma Pipeline with Phase 3 Enrollment on Track
Event summary
- Phase 3 enrollment for BIM-IOL System on track to complete in 2027, targeting ~1M annual cataract procedures.
- First-in-human trial for next-gen BIM-DRS expected to start in H2 2026, expanding addressable patient population.
- $234.2M cash runway extends through 2028, supporting planned operations.
- New CPT code (+1090T) approved for BIM-IOL System, potentially accelerating commercial adoption.
- Q2 2026 net loss widens to $19.9M ($0.59 per share) vs. $8.7M ($3.81 per share) in Q2 2025.
The big picture
SpyGlass Pharma is advancing its glaucoma treatment pipeline with two key product candidates targeting a substantial addressable patient population. The company's progress in securing reimbursement pathways and expanding surgeon engagement reflects strategic positioning ahead of potential commercialization. With a robust cash runway, SpyGlass appears well-funded to execute on its clinical and commercial objectives through 2028.
What we're watching
- Regulatory Pathway
- Whether the new CPT code will materially accelerate BIM-IOL System adoption post-approval.
- Pipeline Execution
- The pace at which SpyGlass can transition from Phase 3 completion to NDA submission for BIM-IOL System.
- Commercial Scaling
- How effectively the strengthened commercial leadership team positions BIM-IOL System for market launch.